Pacira BioSciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PCRX | COLL | ALVO | 42C.SI | 2M7C.F | AQST | |
|---|---|---|---|---|---|---|
| Market cap | 1.45B | 770.59M | 1.67B | 515.12M | 2.87B | 476.94M |
| P/E (TTM) | 104.0 | 18.6 | — | — | 14.8 | — |
| Forward P/E | 10.5 | 3.3 | 20.3 | 247.4 | — | -6.7 |
| Price/book | 2.2 | 2.5 | -8.7 | 33.6 | 1.2 | -13.8 |
| Dividend yield | — | — | — | — | 3.42% | — |
| 1-year change | +66.54% | −33.81% | −6.97% | +259.26% | −28.57% | −35.33% |
| Today | +0.03% | −0.25% | +2.86% | −3.09% | +2.61% | −2.06% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All PCRX news ›Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc
The Ashurst Perkins Coie team was led by Partner Jason Day, with a core team of Partners Jeff Beuche, Lisa McGimpsey, and Jon Schulman; Counsels Jackie Wilcox and Numaan Deen; and Associates Margaret Heitjan and Dani Buckles. To learn…
Potentia trades blows with ex-star dealmaker in profits stand-off
AFR Private equity firm Potentia Capital is embroiled in a bitter legal stoush with its former star dealmaker over allegations he used confidential information that he gained while working at the private equity firm to go after a pote
Vivos to buy 50% stake in SOD Sciences pseudohypoxia test
Vivos Therapeutics has entered into a definitive agreement for an 11% fully diluted equity interest in SOD Sciences along with a 50% undivided co-ownership stake in its pseudohypoxia early-warning diagnostic test. Under the terms of the…
JSA advises Biomapas Group on acquisition of Pinnaxis
Biomapas Group, a portfolio company of Carbyne Equity Partners, has acquired Pinnaxis IT Solutions and Consulting Private Limited, a pharmacovigilance technology and consulting company. JSA Advocates and Solicitors advised the Biomapas…
Vivos Therapeutics to acquire minority stake in SOD Sciences in $12M stock transaction
Vivos Therapeutics (VVOS) agrees to buy 11% of SOD Sciences and co-own a pseudohypoxia early-warning test—deal terms, margins, and Nasdaq impact. - Vivos Therapeutics (VVOS) signed an agreement to acquire an 11% fully diluted equity stake…
Viatris agrees to acquire Pacira for $1.65B
Completion is expected by the end of 2026, subject to the tender condition and regulatory waiting period. The agreement sets an April 2027 outside date and a contingent $62 million termination fee. Viatris has signed the Pacira acquisition…
Agilent to Acquire Digital Pathology Provider Proscia for Up to $270M
Clinical Lab Products The all-cash transaction pairs Agilent's diagnostic instruments and reagents with Proscia's FDA-cleared, vendor-agnostic software platform Agilent Technologies has entered into a definitive agreement to acqu
More from 1 other outlet
Agilent to buy Proscia for $240M
The digital pathology firm “fits in very well” with Agilent and moves the company into a sector targeted by Roche, analysts said. Focused on the U.S. and Europe, Proscia serves more than 4,000 laboratories, hospitals and clinics, as well…
Agilent to buy pathology software maker Proscia for $240 million
Your Privacy is Important to us Opt out of the sale or sharing of personal information Agilent to buy pathology software maker Proscia for $240 million Privately held Proscia develops software that converts pathology slides into digital…
Pacira BioSciences: DOMA reports 0% ownership
Seven investors report stakes below 5% in Pacira BioSciences (PCRX). Stock Titan - [SCHEDULE 13D/A] Pacira BioSciences, Inc. Amended Major Shareholder Report Pacira BioSciences: DOMA reports 0% ownership The ownership-percentage…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com18
- stocktitan.net9
- seekingalpha.com5
- themarketsdaily.com5
- defenseworld.net3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 82 articles, not a forecast.